Raltitrexed
As of the edition of 20 October 2026, Raltitrexed is a small molecule: marketed, first approved in 1996 (FR); acts on TYMS.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1998
- Kind
- Small molecule
- Brand name
- Tomudex
- First approved
- 23 February 1996 (FR)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Pfizer
- Registered trials
- 46, 0 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Lungs and airways; Ear, nose and throat; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TYMS | Thymidylate synthase | P04818 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 6 | 0 | 0 |
| Phase 2 | 30 | 8 | 2 | 0 |
| Phase 3 | 6 | 2 | 0 | 0 |
| Phase 4 | 3 | 0 | 0 | 0 |
| All trials | 46 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant | 1996 to now |